Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/3/2025

Tirzepatide Initiation and Titration in Type 2 Diabetes

Patient Selection and Dosing

  • The American College of Cardiology recommends starting with tirzepatide 2.5 mg subcutaneously once weekly for 4 weeks, followed by a titration to 5 mg once weekly at week 5-8, and further increase to 10 mg once weekly at week 9-12 if additional glycemic control or weight loss is needed 1, 2
  • The American College of Cardiology suggests that the titration should occur in 4-week intervals to allow adequate time for gastrointestinal adaptation and assessment of glycemic response 1

Medication Adjustments to Prevent Hypoglycemia

  • The American College of Cardiology recommends reducing total daily insulin dose by approximately 20% at tirzepatide initiation, and monitoring glucose closely for the first 4 weeks, with further adjustments as needed 3
  • The American Diabetes Association suggests continuing metformin or SGLT2 inhibitors without dose adjustment when starting tirzepatide, as they provide complementary cardiovascular and renal benefits 2, 4

Critical Safety Monitoring

  • The American College of Cardiology advises against using tirzepatide in patients with a personal or family history of medullary thyroid cancer, multiple endocrine neoplasia type 2 (MEN2), or severe hypersensitivity to tirzepatide 1
  • The American College of Cardiology recommends educating patients to report severe abdominal pain immediately and discontinuing tirzepatide if pancreatitis is suspected, with no restart if pancreatitis is confirmed 1, 3

Expected Outcomes and Treatment Goals

  • The American Diabetes Association suggests reassessing HbA1c at 12 weeks, and advancing to the next dose level if not at individualized target 2
  • The Kidney International journal reports that tirzepatide slows eGFR decline by 2.2 mL/min/1.73 m² per year compared to insulin, and reduces UACR by 31-55% in patients with baseline albuminuria 4

Tirzepatide Prescription Guidelines for Type 2 Diabetes

Clinical Context and Patient Selection

  • The American Diabetes Association and other guideline societies recommend tirzepatide as an adjunct to diet and exercise for adults with type 2 diabetes who have not achieved individualized glycemic targets despite use of metformin and SGLT2 inhibitors, or who are unable to use those medications, with a potential HbA1c reduction of 1.87-2.59% and weight loss of 6.2-12.9 kg 5
  • Tirzepatide is particularly appropriate for patients with obesity and type 2 diabetes, and can be used in patients with eGFR ≥30 mL/min/1.73 m² without dose adjustment 5, 6

Important Safety Considerations and Monitoring

  • The American Association of Clinical Endocrinologists notes that hypoglycemia risk is low when tirzepatide is used alone or with metformin, but when combined with insulin or sulfonylureas, doses of these agents should be reduced to prevent hypoglycemia 5
  • The European Association for the Study of Diabetes recommends avoiding combination with DPP-4 inhibitors, and monitoring for signs of pancreatitis, with tirzepatide not adequately studied in kidney transplant recipients 5